Quantum-Si Incorporated - QSI STOCK NEWS

Tesseract Health has appointed Michael McConnell, MD, MSEE, as Head of Cardiovascular and Digital Health, strengthening its leadership under CEO Vicky Demas. Dr. McConnell brings expertise from Google Health and aims to guide the development of cardiovascular health products using Tesseract's non-invasive technology. The company is focused on democratizing health screening and aims to innovate ocular health diagnostics. Tesseract is part of 4Catalyzer, which includes companies like Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), and Hyperfine (NASDAQ: HYPR).

Quantum-Si Incorporated (NASDAQ: QSI), a leader in single molecule protein sequencing, will disclose its first quarter 2022 financial results post-market on May 9, 2022. A conference call for discussing these results and providing a business update is scheduled for 4:30 p.m. ET on the same day. The company's innovative technologies aim to transform proteomics by utilizing a unique semiconductor chip to enhance drug discovery and diagnostics.

Quantum-Si Incorporated (NASDAQ: QSI) announced participation in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference. Scheduled for April 7, 2022, at 10:20 am ET, the presentation will focus on the company's innovative approach to single molecule protein sequencing aimed at revolutionizing proteomics and advancing drug discovery. Interested listeners should contact their B. Riley Securities representatives for access. Quantum-Si’s technology leverages a unique semiconductor chip for enhanced proteomic research.

Quantum-Si (Nasdaq: QSI) reported its Q4 and fiscal year 2021 results, revealing significant increases in operating expenses totaling $27.8 million in Q4, leading to a net loss of $29.4 million. For the fiscal year, total net loss reached $95.0 million, up from $36.6 million in 2020. The company ended the year with $471.3 million in cash and equivalents, positioning it well for upcoming product launches in 2022. They formed a new Scientific Advisory Board, expanded staff from 72 to 153, and entered strategic partnerships to enhance research applications.

Quantum-Si (NASDAQ: QSI) announced its participation in the 42nd Annual Cowen Health Care Conference, scheduled for March 8, 2022, at 2:10 pm ET. The presentation will be held virtually, and interested parties can access a live webcast on the Quantum-Si investor website. A replay will be available post-event. Quantum-Si is pioneering the field of proteomics with its innovative semiconductor chip that enables single molecule protein sequencing, advancing drug discovery and diagnostics.

Quantum-Si (NASDAQ: QSI) announced the appointment of Dr. Jonathan Rothberg as Interim CEO, effective February 8, 2022. Dr. Rothberg, founder and Executive Chairman, will lead the company during the transition as it searches for a permanent CEO. Quantum-Si focuses on revolutionary single molecule protein sequencing, similar to the impact of DNA sequencing in oncology. The company aims to commercialize its groundbreaking technology in 2022, emphasizing its importance in understanding immune responses to COVID-19. Financial results for Q4 and full year 2021 will be reported on February 28, 2022.

Quantum-Si Incorporated (Nasdaq: QSI) will report fourth quarter and full year 2021 financial results after market close on February 28, 2022. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. Quantum-Si focuses on commercializing a unique single molecule protein sequencing platform, aiming to revolutionize proteomics and advance drug discovery. Founded in 2013 by Dr. Jonathan Rothberg, the company utilizes an innovative semiconductor chip designed for next-generation protein sequencing.

Quantum-Si Incorporated (Nasdaq: QSI) announced key updates ahead of the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. They established list prices for their protein sequencing platform: $70,000 for the Platinum^TM Analyzer and $20,000 for the Carbon^TM sampler, with pre-orders starting in H1 2022. The company also published a technical manuscript on bioRxiv, detailing advancements in single-molecule protein sequencing. CEO John Stark emphasized the company's growth momentum and plans for commercialization in 2022.

Quantum-Si (QSI) announced its relocation to new headquarters at the Winchester Works site in Guilford, Connecticut, in the first half of 2022. The 65,000 square-foot facility will enhance R&D and office space, furthering QSI's mission to advance protein sequencing technology. This strategic move follows the opening of a San Diego facility in late 2021, emphasizing QSI's commitment to growth in vital life sciences hubs. The CEO highlighted the importance of these campuses for talent recruitment ahead of the platform's commercial launch.